Peptide coacervate-Prussian blue hybrid supraparticle-tailored scaffolds for revitalizing diabetic heart valve regeneration via multiplex oxidative stress regulation.

Fan Y, Xingzhuang D, Zhiyu Z, Gaoyang G, Yunbing W

Biomaterials22 Oct 2025Cited by 1 (Europe PMC)

PMID41145022DOI10.1016/j.biomaterials.2025.123798PepBankPUB-41145022

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rabbit vascular models, the scaffold accelerated formation of a functional endothelial layer.
In plain wordsIn diabetic rabbits, a scaffold carrying SS‑31, an REDV peptide and Prussian blue sped up formation of a working endothelial layer.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseFunctional endothelial layer formation
Study
rabbitn: not reported in source
diabetic vascular implantation
Outcome group
Wound healing · Cardiovascular
Source sentences
Summary
this scaffold accelerated the formation of a functional endothelial layer and promoted favorable extracellular matrix remodeling.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502207
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In diabetic rabbit vascular models, the scaffold promoted favorable extracellular matrix remodeling.
In plain wordsIn diabetic rabbits, a scaffold carrying SS‑31, an REDV peptide and Prussian blue promoted favorable tissue matrix remodeling.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseExtracellular matrix remodeling
Study
rabbitn: not reported in source
diabetic vascular implantation
Outcome group
Wound healing · Cardiovascular
Source sentences
Summary
promoted favorable extracellular matrix remodeling.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502208
03LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
A scaffold with an SS‑31/REDV peptide coacervate on Prussian blue nanoparticles selectively enhanced endothelial cell adhesion via the REDV motif.
In plain wordsIn cells, a scaffold carrying SS‑31, an REDV peptide and Prussian blue improved endothelial cell attachment.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseEndothelial cell adhesion
Study
n: not reported in source
endothelial cells
Outcome group
Wound healing · Cardiovascular
Source sentences
Summary
selectively enhanced endothelial cell (EC) adhesion via the REDV motif
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502201
04LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
Under hyperglycemic conditions, the scaffold with the SS‑31/REDV/Prussian blue supraparticle reduced endothelial cell apoptosis.
In plain wordsIn cells under high glucose, a scaffold carrying SS‑31, an REDV peptide and Prussian blue reduced endothelial cell death.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseEndothelial cell apoptosis
Study
n: not reported in source
endothelial cells, hyperglycemic conditions
Outcome group
Wound healing · Cardiovascular
Source sentences
Summary
the scaffold reduced EC apoptosis and promoted EC proliferation and migration under hyperglycemic conditions
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502202
05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
Under hyperglycemic conditions, the scaffold with the SS‑31/REDV/Prussian blue supraparticle promoted endothelial cell proliferation.
In plain wordsIn cells under high glucose, a scaffold carrying SS‑31, an REDV peptide and Prussian blue increased endothelial cell growth.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseEndothelial cell proliferation
Study
n: not reported in source
endothelial cells, hyperglycemic conditions
Outcome group
Wound healing · Cardiovascular
Source sentences
Summary
promoted EC proliferation and migration under hyperglycemic conditions
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502203
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
Under hyperglycemic conditions, the scaffold with the SS‑31/REDV/Prussian blue supraparticle promoted endothelial cell migration.
In plain wordsIn cells under high glucose, a scaffold carrying SS‑31, an REDV peptide and Prussian blue increased endothelial cell movement.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseEndothelial cell migration
Study
n: not reported in source
endothelial cells, hyperglycemic conditions
Outcome group
Wound healing · Cardiovascular
Source sentences
Summary
promoted EC proliferation and migration under hyperglycemic conditions
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502204
07LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
The scaffold alleviated hyperglycemia-induced oxidative stress in macrophages.
In plain wordsIn cells, a scaffold carrying SS‑31, an REDV peptide and Prussian blue eased high-glucose oxidative stress in macrophages.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMacrophage oxidative stress
Study
n: not reported in source
macrophages, hyperglycemia
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
the scaffold alleviated hyperglycemia-induced oxidative stress in macrophages, thereby suppressing inflammatory cytokine expression.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502205
08LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
The scaffold suppressed inflammatory cytokine expression in macrophages under hyperglycemia.
In plain wordsIn cells, a scaffold carrying SS‑31, an REDV peptide and Prussian blue lowered inflammatory cytokine expression in macrophages.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory cytokine expression
Study
n: not reported in source
macrophages, hyperglycemia
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
Moreover, the scaffold alleviated hyperglycemia-induced oxidative stress in macrophages, thereby suppressing inflammatory cytokine expression.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4114502206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.